A new company has been set up in the UK to acquire clinical assets that large pharma companies may not be in a position to develop further. The first programmes acquired by Mereo BioPharma Group Ltd are three mid-stage clinical assets from Novartis.
Sanofi SA reported revenue of €9.4 billion in the 2015 second quarter, up by 16.1% on a reported basis, driven in part by sales from its Genzyme unit and a strengthening of the dollar against the euro. At constant exchange rates, the increase was 4.9%.
Pharming Group NV more than doubled its revenue in the 2015 first-half as sales of Ruconest, its treatment for hereditary angioedema (HAE) gained momentum following US regulatory approval in July 2014. The approval came nearly four years after the drug was authorised in Europe.
AstraZeneca Plc reported revenue of $6.3 billion for the second quarter, which was an increase of 2% when expressed in constant exchange rates, enabling the company to declare six successive quarters of top-line growth and to revise upward its guidance for 2015.
GlaxoSmithKline Plc expects to see earnings grow again in 2016 following a reshaping of its business to focus on pharmaceuticals, vaccines and consumer healthcare and reducing its dependence on the off-patent respiratory medicine Advair.
MorphoSys AG has confirmed its financial guidance for 2015 with expectations of revenue of between €101 and €106 million, and earnings before interest and tax of €9 to €16 million. This follows an eventful period during which it saw a multi-year partnership with Celgene Corp end.
A three-year collaboration between Ablynx NV and Merck & Co. Inc in immuno-oncology has been extended by one year in order to enable the parties to investigate up to 12 new molecules targeting individual protein targets and combinations of targets that could potentially treat cancer, Ablynx announced the new agreement on 22 July.
A new vaccine designed to protect young children in sub-Saharan Africa from infection from thePlasmodium falciparum parasite has been given a positive opinion by the European Medicines Agency even as its effectiveness was described as modest.
Oxford Nanopore Technologies Ltd has raised £70 million through a private placement of shares with new and existing investors in the UK, US and continental Europe to support development of the company’s electronic molecular analysis systems.
Roche has confirmed its forecast for a modest growth in sales this year with core earnings per share advancing ahead of sales. In the first half, the increase in sales was restrained by a strengthening of the Swiss franc against the euro.